XML 176 R53.htm IDEA: XBRL DOCUMENT
v3.25.1

Long-Term Investments - Schedule of Long-Term Investment (Details) - USD ($) | Mar. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023
--- | --- | --- | ---
Non-marketable Cost Method Investments, net |  |  |  |  |  |  |
Non-marketable Cost Method Investments, net |  | $ 779,791 |  | $ 790,250 |  | $ 847,252 |
Equity Method Investments, net |  |  |  |  |  |  |
Equity Method Investments, net |  | 2,760,062 |  | 2,258,754 |  | 2,527,740 |
Braingenesis Biotechnology Co., Ltd. [Member] |  |  |  |  |  |  |
Non-marketable Cost Method Investments, net |  |  |  |  |  |  |
Non-marketable Cost Method Investments, net |  | 6,640 |  | 6,727 |  | 7,213 |
Genepharm Biotech Corporation [Member] |  |  |  |  |  |  |
Non-marketable Cost Method Investments, net |  |  |  |  |  |  |
Non-marketable Cost Method Investments, net |  | 20,271 |  | 20,540 |  | 22,021 |
ForSeeCon Eye Corporation [Member] |  |  |  |  |  |  |
Non-marketable Cost Method Investments, net |  |  |  |  |  |  |
Non-marketable Cost Method Investments, net | [1] |  |  |  |  |  |
BioHopeKing Corporation [Member] |  |  |  |  |  |  |
Non-marketable Cost Method Investments, net |  |  |  |  |  |  |
Non-marketable Cost Method Investments, net |  | 752,880 |  | 762,983 |  | 818,018 |
BioFirst Corporation [Member] |  |  |  |  |  |  |
Equity Method Investments, net |  |  |  |  |  |  |
Equity Method Investments, net |  | 1,420,800 | [2] | 1,468,504 | [2],[3] | 1,680,488 | [3]
Rgene Corporation [Member] |  |  |  |  |  |  |
Equity Method Investments, net |  |  |  |  |  |  |
Equity Method Investments, net |  | 559,471 | [4] |  | [4],[5] |  | [5]
BioLite Japan K.K. (BioLite JP) [Member] |  |  |  |  |  |  |
Equity Method Investments, net |  |  |  |  |  |  |
Equity Method Investments, net | [6] |  |  |  |  |  |
OncoX BioPharma, Inc. [Member] |  |  |  |  |  |  |
Equity Method Investments, net |  |  |  |  |  |  |
Equity Method Investments, net | [7] |  |  |  |  |  |
[1] | ForSeeCon Eye Corporation (FEYE) FEYE is a private company registered in the British Virgin Islands, focusing on the field of diagnosis and treatment of eye disorders, with its main product of Vitargus. The Company granted FEYE certain licensed products in exchange of FEYE ownership. See Note 4 for detail of such transactions.
[2] | BioFirst Corporation (the “BioFirst”): The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2025 and December 31, 2024, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of March 31, 2025 and December 31, 2024, the amount of prepayment for long-term investments in Biofirst is both $1,124,842.
[3] | BioFirst Corporation (the “BioFirst”): The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of December 31, 2024, the amount of prepayment for long-term investments in Biofirst is $1,124,842.
[4] | Rgene Corporation (the “Rgene”) As described in Note 4, the Company acquired 26.65% of Rgene’s outstanding common shares since 2018 through multiple collaborative agreements, and has been accounting this equity investment with equity method as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. Further, as disclosed in Note 10 Related Party Transactions, the Company entered a convertible loan agreement with Rgene in 2022 and has been working with Rgene to obtain approval for the Company to exercise the conversion from Department of Investment Review in Taiwan, a government agency reviews foreign investors conducting investment in Taiwan. In May 2024, the conversion request for the conversion was approved but the Company was not informed by Rgene until April 2025. The Company determined that the impact to the financial statements is immaterial and assumed the conversion was incurred on January 1, 2025. After the conversion, the Company owns 37% of outstanding shares of Rgene.
[5] | Rgene Corporation (the “Rgene”) Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of December 31, 2024 and 2023, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively.
[6] | BioLite Japan K.K. (BioLite JP) In October 2021, the Company, Lucidaim Co., Ltd., a Japanese corporation (“Lucidaim,” together with the Company, the “Shareholders”), and BioLite Japan K.K., a Japanese corporation (“BioLite JP”) entered into a Joint Venture Agreement. BioLite JP is a private limited company incorporated on December 18, 2018. The business of the joint venture is the research and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements carried on by BioLite JP and its subsidiaries in Japan, or any other territory or businesses. At the date of the Agreement, BioLite JP has 10,000 ordinary shares authorized, with 3,049 ordinary shares issued and outstanding (the “Ordinary Shares”). Pursuant to the Agreement and the related share transfer agreement, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). The Company paid $150,000 towards the setup of the joint venture; BioLite Japan’s other shareholder also paid $150,000 after the Letter of Intent was signed. This prepayment is booked in prepayment for investment. As of December 31, 2024, the Company evaluated the investee’s business and financial conditions and determined to fully impair such prepayment.
[7] | OncoX BioPharma, Inc. (OncoX) OncoX is a private company registered in the British Virgin Islands, focusing on oncology trials and drug development across Asia-Pacific. The Company granted OncoX certain licensed products in exchange of OncoX’s ownership. See Note 4 for detail of such transactions.

X
- References No definition available. + Details
Name: | abvc_EquityMethodInvestmentsNetAbstract
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_NonMarketableCostMethodInvestmentsNetAbstract
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent. + References No definition available. + Details
Name: | us-gaap_DebtSecuritiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_LongTermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_ForSeeConEyeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanKKBioLiteJPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvc_OncoXBioPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |